Adherence Level to secondary prophylaxis among students aged 5-20 years with confirmed rheumatic heart disease following school-based screening in South Ethiopia

In the quiet corners of the heart, a silent battle can begin long before a child ever feels sick. It starts with a common sore throat, an infection caused by a specific type of bacteria that most people shake off without a second thought. But for some, the body's immune system overreacts to this infection, launching an attack that mistakenly damages its own tissues. This autoimmune response can scar the heart valves, leading to a condition called rheumatic heart disease. Once the valves are damaged, they cannot open or close properly, forcing the heart to work harder and eventually leading to heart failure or premature death. The World Health Organization recommends a simple, monthly shield against this progression: a long-acting antibiotic injection that prevents the bacteria from returning. This treatment is not a cure for the damage already done, but it is a vital defense that stops the disease from getting worse. For children and teenagers, however, sticking to this monthly schedule is often the hardest part of the battle.

A recent investigation in southern Ethiopia sought to understand why so many young patients struggle to keep this promise to their own health. Researchers traveled to the Wolaita Zone, a region where a dedicated program has been screening schoolchildren for heart disease since 2017. They focused on 202 students, aged five to twenty, who had been confirmed to have rheumatic heart disease and were enrolled in a program to receive these monthly penicillin injections. The team did not rely on guesswork or memory; instead, they cross-referenced interviews with the children and their families against the actual medical records of every single injection given over the past year. They wanted to see who was keeping up with the treatment and who was falling behind, and more importantly, they wanted to know what was making the difference.

The results painted a stark picture of the challenges facing these young patients. Out of the 202 students studied, nearly two-thirds had missed enough doses to be considered non-adherent to the treatment plan. In plain terms, 126 of these children were not receiving the protection they needed to stop their heart disease from progressing. The researchers found that this high rate of missed doses was not random; it was tied to specific, tangible barriers in the children's daily lives. The most powerful factor was simply where a child lived. Those residing in rural areas were far more likely to miss their appointments than their peers in towns. Distance played an equally critical role; children whose homes were more than 30 kilometers from the hospital were significantly less likely to stick to the schedule. The journey itself, likely involving difficult roads and the cost of travel, appeared to be a major obstacle.

Time, too, proved to be a formidable enemy of consistency. The study revealed that the longer a child had been on the treatment, the harder it became to stay on track. Students who had been receiving injections for more than five years were much more likely to have poor adherence compared to those who had been treated for a shorter time. This suggests that the initial motivation to get better fades over the years, replaced by the fatigue of a lifelong routine. Beyond geography and time, the researchers uncovered a web of other difficulties. Many families faced a lack of counseling about why the injections were necessary, and a significant number of children feared the pain of the needle or worried that the medicine itself could harm their hearts. Some children even believed that if they felt fine, they could stop the treatment, a dangerous misconception that could undo years of progress.

The study did not find that age or gender were the deciding factors in whether a child stayed on treatment. Instead, the evidence pointed clearly toward the environment surrounding the patient. The difficulty of traveling to a distant hospital, the isolation of rural living, and the sheer exhaustion of maintaining a strict medical routine for years created a perfect storm for missed doses. The researchers noted that while the program had successfully identified these children through school screenings, the system for keeping them healthy was straining under the weight of these logistical and psychological barriers. The findings suggest that simply having the medicine available is not enough; the path to the clinic must be clear, and the support for the patient must be continuous.

Ultimately, this work highlights a gap between medical knowledge and daily reality. The science of preventing heart failure is well understood, and the tool to do it exists. Yet, for a large portion of these children, the bridge between the clinic and their home is too long, too expensive, or too difficult to cross regularly. The study concludes that to save these young lives, the approach must change. It calls for bringing the treatment closer to where people live, reducing the distance they must travel, and providing better support to help families manage the long-term commitment of care. Without these changes, the cycle of missed doses and worsening heart disease will likely continue, turning a preventable condition into a tragic outcome for a generation of children who simply could not make it to the clinic in time.